Literature DB >> 32087877

Reply.

Freekje van Asten1, Chi-Yang Chiu2, Elvira Agrón3, Traci E Clemons4, Rinki Ratnapriya1, Anand Swaroop1, Michael L Klein5, Ruzong Fan6, Emily Y Chew7.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32087877      PMCID: PMC8336683          DOI: 10.1016/j.ophtha.2019.10.033

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  5 in total

1.  Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration: Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study.

Authors:  Melissa J Assel; Fan Li; Ying Wang; Andrew S Allen; Keith A Baggerly; Andrew J Vickers
Journal:  Ophthalmology       Date:  2017-10-09       Impact factor: 12.079

2.  Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test?

Authors:  Emily Y Chew; Michael L Klein; Traci E Clemons; Elvira Agrón; Gonçalo R Abecasis
Journal:  Ophthalmology       Date:  2014-11-18       Impact factor: 12.079

3.  Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study.

Authors:  Carl C Awh; Steven Hawken; Brent W Zanke
Journal:  Ophthalmology       Date:  2014-09-04       Impact factor: 12.079

4.  No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38.

Authors:  Emily Y Chew; Michael L Klein; Traci E Clemons; Elvira Agrón; Rinki Ratnapriya; Albert O Edwards; Lars G Fritsche; Anand Swaroop; Gonçalo R Abecasis
Journal:  Ophthalmology       Date:  2014-06-26       Impact factor: 12.079

5.  CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration.

Authors:  Carl C Awh; Anne-Marie Lane; Steven Hawken; Brent Zanke; Ivana K Kim
Journal:  Ophthalmology       Date:  2013-08-21       Impact factor: 12.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.